The NMDA receptor co-agonists, d-serine and glycine, regulate neuronal dendritic architecture in the somatosensory cortex

Neurobiology of Disease

Volumn 45, Issue 2, 2012, Pages 671-682

  Balu, Darrick T ^a,b   Basu, Alo C ^a,b   Corradi, John P ^c   Cacace, Angela M ^c   Coyle, Joseph T ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MCLEAN HOSPITAL   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

BDNF; Dendritic spines; Glycine; NMDA receptor; Schizophrenia; Serine racemase; Somatosensory cortex

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; GLYCINE; GLYCINE TRANSPORTER; MESSENGER RNA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; RACEMASE; SERINE RACEMASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN LEVEL; BRAIN REGION; BRAIN SIZE; CELL DENSITY; CELL STRUCTURE; CONTROLLED STUDY; DENDRITIC SPINE; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENETIC ASSOCIATION; MOUSE; NEUROPATHOLOGY; NEUROPIL; NONHUMAN; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; SCHIZOPHRENIA; SOMATOSENSORY CORTEX; WILD TYPE;

ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; DENDRITES; GENE EXPRESSION PROFILING; GLYCINE; IMMUNOHISTOCHEMISTRY; MICE; MICE, KNOCKOUT; NEURONS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RACEMASES AND EPIMERASES; RECEPTORS, N-METHYL-D-ASPARTATE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SCHIZOPHRENIA; SERINE; SOMATOSENSORY CORTEX;

EID: 84855794777     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2011.10.006     Document Type: Article

References (72)

1. Balu D.T., Coyle J.T. Glutamate receptor composition of the post-synaptic density is altered in genetic mouse models of NMDA receptor hypo- and hyperfunction. Brain Res. 2011, 1392:1-7.
2. Balu D.T., Coyle J.T. Neuroplasticity signaling pathways linked to the pathophysiology of schizophrenia. Neurosci. Biobehav. Rev. 2011, 35:848-870.
3. Bass N.J., et al. Evidence for the association of the DAOA (G72) gene with schizophrenia and bipolar disorder but not for the association of the DAO gene with schizophrenia. Behav. Brain Funct. 2009, 5:28.
4. Basu A.C., et al. Targeted disruption of serine racemase affects glutamatergic neurotransmission and behavior. Mol. Psychiatry 2009, 14:719-727.
5. Binder D.K., Scharfman H.E. Brain-derived neurotrophic factor. Growth Factors 2004, 22:123-131.
6. Chen Y., et al. Intramembranous valine linked to schizophrenia is required for neuregulin 1 regulation of the morphological development of cortical neurons. J. Neurosci. 2010, 30:9199-9208.
7. Coyle J.T. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell. Mol. Neurobiol. 2006, 26:365-384.
8. Datwani A., et al. NMDA receptor-dependent pattern transfer from afferents to postsynaptic cells and dendritic differentiation in the barrel cortex. Mol. Cell. Neurosci. 2002, 21:477-492.
9. DeVito L.M., et al. Serine racemase deletion disrupts memory for order and alters cortical dendritic morphology. Genes Brain Behav. 2011, 10:210-222.
10. Doniger G.M., et al. Impaired visual object recognition and dorsal/ventral stream interaction in schizophrenia. Arch. Gen. Psychiatry 2002, 59:1011-1020.
11. Erhardt S., et al. The kynurenic acid hypothesis of schizophrenia. Physiol. Behav. 2007, 92:203-209.
12. Fiala J.C., et al. Dendritic spine pathology: cause or consequence of neurological disorders?. Brain Res. Brain Res. Rev. 2002, 39:29-54.
13. Galvez R., Greenough W.T. Sequence of abnormal dendritic spine development in primary somatosensory cortex of a mouse model of the fragile X mental retardation syndrome. Am. J. Med. Genet. A 2005, 135:155-160.
14. Garey L.J., et al. Reduced dendritic spine density on cerebral cortical pyramidal neurons in schizophrenia. J. Neurol. Neurosurg. Psychiatry 1998, 65:446-453.
15. Glantz L.A., Lewis D.A. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch. Gen. Psychiatry 2000, 57:65-73.
16. Goldman A.L., et al. Widespread reductions of cortical thickness in schizophrenia and spectrum disorders and evidence of heritability. Arch. Gen. Psychiatry 2009, 66:467-477.
17. Hashimoto K., et al. Decreased serum levels of d-serine in patients with schizophrenia: evidence in support of the N-methyl-d-aspartate receptor hypofunction hypothesis of schizophrenia. Arch. Gen. Psychiatry 2003, 60:572-576.
18. Hashimoto K., et al. Reduced d-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 2005, 29:767-769.
19. Hashimoto T., et al. Relationship of brain-derived neurotrophic factor and its receptor TrkB to altered inhibitory prefrontal circuitry in schizophrenia. J. Neurosci. 2005, 25:372-383.
20. Hattori T., et al. A novel DISC1-interacting partner DISC1-Binding Zinc-finger protein: implication in the modulation of DISC1-dependent neurite outgrowth. Mol. Psychiatry 2007, 12:398-407.
21. Huang E.J., Reichardt L.F. Trk receptors: roles in neuronal signal transduction. Annu. Rev. Biochem. 2003, 72:609-642.
22. Ide M., Lewis D.A. Altered cortical CDC42 signaling pathways in schizophrenia: implications for dendritic spine deficits. Biol. Psychiatry 2010, 68:25-32.
23. Iwasat T., et al. Cortex-restricted disruption of NMDAR1 impairs neuronal patterns in the barrel cortex. Nature 2000, 406:726-731.
24. Iwasato T., et al. NMDA receptor-dependent refinement of somatotopic maps. Neuron 1997, 19:1201-1210.
25. Jaaro-Peled H. Gene models of schizophrenia: DISC1 mouse models. Prog. Brain Res. 2009, 179:75-86.
26. Javitt D.C. Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients. Curr. Opin. Psychiatry 2006, 19:151-157.
27. Javitt D.C. When doors of perception close: bottom-up models of disrupted cognition in schizophrenia. Annu. Rev. Clin. Psychol. 2009, 5:249-275.
28. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 1991, 148:1301-1308.
29. Kalus P., et al. The dendritic architecture of prefrontal pyramidal neurons in schizophrenic patients. NeuroReport 2000, 11:3621-3625.
30. Kartvlishvily E., et al. Neuron-derived d-serine release provides a novel means to activate N-methyl-d-aspartate receptors. J. Biol. Chem. 2006, 281:14151-14162.
31. Katsel P., et al. Abnormal indices of cell cycle activity in schizophrenia and their potential association with oligodendrocytes. Neuropsychopharmacology 2008, 33:2993-3009.
32. Kishi N., Macklis J.D. MECP2 is progressively expressed in post-migratory neurons and is involved in neuronal maturation rather than cell fate decisions. Mol. Cell. Neurosci. 2004, 27:306-321.
33. Kolluri N., et al. Lamina-specific reductions in dendritic spine density in the prefrontal cortex of subjects with schizophrenia. Am. J. Psychiatry 2005, 162:1200-1202.
34. Kristiansen L.V., et al. Expression of the NR2B-NMDA receptor trafficking complex in prefrontal cortex from a group of elderly patients with schizophrenia. Schizophr. Res. 2010, 119:198-209.
35. Kristiansen L.V., et al. Expression of the NR2B-NMDA receptor subunit and its Tbr-1/CINAP regulatory proteins in postmortem brain suggest altered receptor processing in schizophrenia. Synapse 2010, 64:495-502.
36. Krystal J.H., et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 1994, 51:199-214.
37. Kuperberg G.R., et al. Regionally localized thinning of the cerebral cortex in schizophrenia. Arch. Gen. Psychiatry 2003, 60:878-888.
38. Kwon H.B., Sabatini B.L. Glutamate induces de novo growth of functional spines in developing cortex. Nature 2011, 474:100-104.
39. Lewis D.A., Gonzalez-Burgos G. Neuroplasticity of neocortical circuits in schizophrenia. Neuropsychopharmacology 2008, 33:141-165.
40. Li C., Wong W.H. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:31-36.
41. Lisman J.E., et al. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci. 2008, 31:234-242.
42. Lu B. BDNF and activity-dependent synaptic modulation. Learn. Mem. 2003, 10:86-98.
43. Lubke J., Feldmeyer D. Excitatory signal flow and connectivity in a cortical column: focus on barrel cortex. Brain Struct. Funct. 2007, 212:3-17.
44. Martin K.P., Wellman C.L. NMDA receptor blockade alters stress-induced dendritic remodeling in medial prefrontal cortex. Cereb. Cortex 2011, 21:2366-2373.
45. Martina M., et al. Reduced glycine transporter type 1 expression leads to major changes in glutamatergic neurotransmission of CA1 hippocampal neurones in mice. J. Physiol. 2005, 563:777-793.
46. Miya K., et al. Serine racemase is predominantly localized in neurons in mouse brain. J. Comp. Neurol. 2008, 510:641-654.
47. Moody T.W., et al. VIP and PACAP: recent insights into their functions/roles in physiology and disease from molecular and genetic studies. Curr. Opin. Endocrinol. Diab. Obes. 2011, 18:61-67.
48. Morita Y., et al. A genetic variant of the serine racemase gene is associated with schizophrenia. Biol. Psychiatry 2007, 61:1200-1203.
49. Paxinos, G., Franklin, K.B.J. The Mouse Brain in Stereotaxic Coordinates, 2nd Edition, Academic Press, 2001.
50. Pellegri G., et al. VIP and PACAP potentiate the action of glutamate on BDNF expression in mouse cortical neurones. Eur. J. Neurosci. 1998, 10:272-280.
51. Peters A., Kaiserman-Abramof I.R. The small pyramidal neuron of the rat cerebral cortex. The perikaryon, dendrites and spines. Am. J. Anat. 1970, 127:321-355.
52. Rajkowska G., et al. Neuronal and glial somal size in the prefrontal cortex: a postmortem morphometric study of schizophrenia and Huntington disease. Arch. Gen. Psychiatry 1998, 55:215-224.
53. Rasser P.E., et al. Gray matter deficits, mismatch negativity, and outcomes in schizophrenia. Schizophr. Bull. 2011, 37:131-140.
54. Rosoklija G., et al. Structural abnormalities of subicular dendrites in subjects with schizophrenia and mood disorders: preliminary findings. Arch. Gen. Psychiatry 2000, 57:349-356.
55. Sacchi S., et al. pLG72 modulates intracellular d-serine levels through its interaction with d-amino acid oxidase: effect on schizophrenia susceptibility. J. Biol. Chem. 2008, 283:22244-22256.
56. Schell M.J., et al. d-serine, an endogenous synaptic modulator: localization to astrocytes and glutamate-stimulated release. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:3948-3952.
57. Selemon L.D., Goldman-Rakic P.S. The reduced neuropil hypothesis: a circuit based model of schizophrenia. Biol. Psychiatry 1999, 45:17-25.
58. Sepulveda F.J., et al. Differential roles of NMDA receptor subtypes NR2A and NR2B in dendritic branch development and requirement of RasGRF1. J. Neurophysiol. 2010, 103:1758-1770.
59. Shi J., et al. Allelic association of G72/G30 with schizophrenia and bipolar disorder: a comprehensive meta-analysis. Schizophr. Res. 2008, 98:89-97.
60. Sweet R.A., et al. Mapping synaptic pathology within cerebral cortical circuits in subjects with schizophrenia. Front. Hum. Neurosci. 2010, 4:44.
61. Takahashi M., et al. Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients. Mol. Psychiatry 2000, 5:293-300.
62. Tsai G.E., Lin P.Y. Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Curr. Pharm. Des. 2010, 16:522-537.
63. Tsai G., et al. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch. Gen. Psychiatry 1995, 52:829-836.
64. Tsai G., et al. Gene knockout of glycine transporter 1: characterization of the behavioral phenotype. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:8485-8490.
65. Wayman G.A., et al. Activity-dependent dendritic arborization mediated by CaM-kinase I activation and enhanced CREB-dependent transcription of Wnt-2. Neuron 2006, 50:897-909.
66. Wayman G.A., et al. An activity-regulated microRNA controls dendritic plasticity by down-regulating p250GAP. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:9093-9098.
67. Weickert C.S., et al. Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol. Psychiatry 2003, 8:592-610.
68. Wolosker H., et al. Serine racemase: a glial enzyme synthesizing d-serine to regulate glutamate-N-methyl-d-aspartate neurotransmission. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:13409-13414.
69. Wong J., et al. Promoter specific alterations of brain-derived neurotrophic factor mRNA in schizophrenia. Neuroscience 2010, 169:1071-1084.
70. Woolsey T.A. Barrels: 25 years later. Somatosens. Mot. Res. 1996, 13:181-186.
71. Woolsey T.A., Van der Loos H. The structural organization of layer IV in the somatosensory region (SI) of mouse cerebral cortex. The description of a cortical field composed of discrete cytoarchitectonic units. Brain Res. 1970, 17:205-242.
72. Zito K., et al. Rapid functional maturation of nascent dendritic spines. Neuron 2009, 61:247-258.